AEM vs CSTM

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

CSTM presents a dichotomy between explosive growth and deteriorating fundamental value. While the Piotroski F-Score of 4/9 indicates stable but mediocre financial health, the stock is trading at a significant premium to its Graham Number ($17.43) and Intrinsic Value ($13.44). Despite a very attractive PEG ratio of 0.40 and strong ROE of 32.39%, the combination of aggressive insider selling by the CEO and CFO and a high Debt/Equity ratio (2.12) suggests the current price may be overextended.